Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Fujian Medical University
Headquarters:
Fuzhou, China
Website:
https://en.fjmu.edu.cn/
Year Founded:
1937
Status:
N/A
Biopharma related deals can be found by searching the organization's name in the
Deals
Module.
BioCentury
|
Dec 16, 2024
Distillery Therapeutics
Splice-altering ASO for primary familial brain calcification
Read More
BioCentury
|
Nov 6, 2024
Distillery Therapeutics
Inhibiting JAK-induced STAT1 signaling for toxic epidermal necrolysis
Read More
BioCentury
|
Oct 2, 2024
Distillery Therapeutics
NUAK1 for gastric cancer chemoresistance
Read More
BioCentury
|
Apr 20, 2023
Discovery & Translation
CRISPR guide RNAs with guardrails, bacterial sensors for pathogen detection and more
BioCentury’s roundup of translational news
Read More
BioCentury
|
Nov 23, 2022
Data Byte
Translational spotlight on East-West innovation
Collaborations between investigators at Asian and Western universities in BioCentury’s Distillery present licensing and partnering opportunities
Read More
BioCentury
|
Apr 8, 2021
Distillery Therapeutics
PON-2 identified as B cell-ALL target
DISEASE CATEGORY: Cancer
INDICATION: Acute lymphoblastic leukemia (ALL) Inhibiting PON2, a lactonase, could treat B cell ALL (B-ALL). Levels of PON2 mRNA were higher in Philadelphia
Read More
Items per page:
10
1 - 6 of 6